http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-193479-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05ff905fdc49089f5f25746eaeb40190
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
filingDate 1996-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1b077c1ec29eb6a537e7fd4e81222ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afcaf9f15e9daefcc4cb52233b2c7c73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32dc1c837140034af309178ce8e46dbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_364e0cb2c88ffd2d42d18e1e0237c9ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69093741e1e272ca30ff4bf6eef729f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42f7cd3c6d20257a7ae117c3e713264d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92ead8f39b0a70eb69f7cf6ed7224d05
publicationDate 2007-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PL-193479-B1
titleOfInvention Atorvastatin hydrate crystalline forms, pharmaceutical composition containing atorvastatin hydrate crystalline form I and its use
abstract There are described novel crystalline forms of ÄR-(R*,R*)Ü-2-(4-fluorophenyl)- beta , delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-Ä(phenylamino)carbonylÜ-1H-pyr role-l-heptanoic acid hemi calcium salt designated Form II and Form IV which are characterized by their X-ray powder diffraction and/or solid state NMR, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia and hypercholesterolemia.
priorityDate 1995-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426114673
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID138115
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458395511
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3156
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6116
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID471516
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID15357
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID479182
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60823
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415838102
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID42803
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID101843185
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25675
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID397750
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457814461
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419519319
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6483036
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419496926
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453447712
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID445127
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID407159
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100144446
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID395145
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID373355

Total number of triples: 52.